Genotypes and subtypes of hepatitis C virus in Burundi: a particularity in Sub-saharan Africa

Rénovat Ntagirabiri1,6, Jean Dominique Poveda2, Annie Mumana1, Hermelance Ndayishimiye1

1Centre des Maladies Digestives et du Foie « CEMADIF », Bujumbura, Burundi, 2Laboratoire Cerba, Paris, France

6Corresponding author: Rénovat Ntagirabiri, Centre des Maladies Digestives et du Foie « CEMADIF », Bujumbura, Burundi

Key words: Hepatitis C virus, genotype, subtype, genotype 4

Received: 15/05/2014 - Accepted: 06/09/2014 - Published: 24/09/2014

Abstract

Introduction: Hepatitis C virus (HCV) infection is a major public health issue. HCV genotype identification is clinically important to tailor the dosage and duration of treatment. Indeed, distinct therapeutic approaches are required for each genotype. Up to now, there is no study assessing HCV genotypes and subtypes in Burundi. The aim of the study was to determine HCV genotypes and subtypes in Burundi and to highlight the difficulties related to LiPA Method, widely used for African samples. Methods: In this study, a total of 179 samples contained anti-HCV antibodies were tested for HCV RNA, genotyping and subtyping. The analysis had been made in Cerba laboratory, Paris, France. Results: 166 patients (92.7%) were genotype 4; 10 patients (5.6%) were genotype 1 and 3 patients (1.7%) were genotype 3. It was possible to determine subtypes for 51 HCV-4 (30.7%) patients. Among these, 25 (49.1%) had 4h subtype; 11 (21.6%) had 4e subtype; 2 (3.9%) had 4k subtype and 13 patients (25.5%) had 4a/4c/4d subtype. The LiPA method failed to subtype 115 (69.3%) HCV-4 and to separate the three subtype: 4a, 4c and 4d. Conclusion: Genotype 4 and subtype 4h followed by 4e are the widespread in Burundi.

Pan African Medical Journal. 2014; 19:69 doi:10.11604/pamj.2014.19.69.4580

This article is available online at: http://www.panafrican-med-journal.com/content/article/19/69/full/

© Rénovat Ntagirabiri et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Hepatitis C virus (HCV) infection is a major public health issue. Global prevalence of HCV is approximately 180 million people [1]. Central Africa has the second highest HCV prevalence: 6.0% of adults overall [2]. In Burundi, HCV prevalence is estimated up to 8.2% [3]. There are at least six genotypes throughout the world, each of them containing subtypes, according to the nucleotide divergence [4]. HCV genotype identification is clinically important to tailor the dosage and duration of treatment because distinct therapeutic approaches are required for each genotype [5]. Duration of treatment for a maximal sustained virological response (SVR) rate depends on genotype. In recent years, there has been an increasing interest in HCV subtype for SVR. Indeed, the subtype 1a could be associated with a lower response to anti-HCV therapy than subtypes 1b, 4a, and 4d [6,7]. Up to now, there is no study assessing HCV genotypes and subtypes in Burundi. A further issue is that the laboratory techniques are validated based on American and European samples and could not be well adapted to African samples. The aim of our study was to determine HCV genotypes and subtypes in Burundi and to highlight the difficulties related to LiPA Method, widely used, about African samples.

Methods

Study population: The study population consisted of consecutive willing patients aged ≥15 years; attending medical cares in CEMADIF since January to May 2013. We included patients with anti-HCV antibodies positive. We excluded patients under interferon treatment or who have achieved the treatment with a SVR.

Study design: This was a cross sectional study. Socioeconomic and clinical data were collected by interview followed by a clinical examination done by a physician. After, patients were directed to the laboratory for blood sampling. In CEMADIF laboratory, all samples were collected and frozen by 4 hours. Molecular analysis was made by Cerba Laboratory, Paris, France. Samples were tested for HCV-RNA, HCV genotyping and subtyping. The quantification of HCV-RNA was made by the rt-PCR Taqman Roche method, with a sensitivity of 15 UI/ml (1.2log) and linearity of 15-100,000,000 UI/ml (1.2-Blog) or by the Abbott RealTime HCV assay technique. The determination of genotype and subtype of HCV was made by rt-PCR technique and reverse-hybridization Line Probe Assay (LiPA) with the reagent SIEMENS VERSANT LiPA HCV2® or by sequencing. Data were collected initially in a specialized data collection form, introduced into a Microsoft Excel worksheet, and finally transferred to the statistical package for social sciences (SPSS) version 10.0 for analysis.

Ethical consideration: Prior to blood sampling, the study was explained by a physician to the patient and a written informed consent was obtained. The tests were free of charge. The national ethics committee of Burundi approved the study.

Results

During the period of the study, a total of 179 samples containing anti-HCV antibodies, from 179 consent patients, were collected and tested for HCV-RNA, HCV genotyping and subtyping.

Patient’s characteristics: A total of 105 (58.6%) females and 74 (41.4%) males had been enrolled. The mean age was 51.4 year (22 years to 73 years). The Figure 1 illustrates the distribution of patients per age. 123 (68.7%) were business men, 90 (50.3%) had a high school certificate and 55 (30.7%) had a bachelors degree. 122 (68.1%) were married while 31 (17.3%) were widows (ers). The patients were native of all provinces of the country. 103 (57.5%) resided in Bujumbura City. The HCV RNA was detected among all patients with the extremes of 113 UI/ml (2.05log) and 20208194 UI/ml (7.30log). Table 1 illustrates the viral load (VL) according to VHC-4 subtypes.

Genotypes and subtypes: 166 patients (92.7%) were genotype 4 (HCV-4), 10 patients (5.6%) were genotype 1, and 3 patients (1.7%) were genotype 3. Table 2 illustrates different genotypes and subtypes. Indeed, it was possible to determine subtypes for 51 HCV-4 (30.7%). Among these 51 patients, 25 (49.1%) had 4h subtype, 11 (21.6%) had 4e subtype, 2 (3.9%) had a subtype 4k and 13 patients (25.5%) had 4a/4c/4d subtype. The LiPA method didn’t allow to classify to one or other of these three 4a, 4c, 4d subtypes. For the 115 remaining HCV 4 (69.3%) it was not possible to determine subtype. Otherwise, some patients were erroneously classified by the LiPA technique in subtype 3k. For genotype 1, the subtype was specified only for one patient as 1a.
Discussion

Our study indicates that HCV-4 is the most widespread HCV genotype in Burundi. This result can be extrapolated somehow to general population because patients were native of all provinces of the country. Our HCV-4 prevalence results in Burundi (92%) are also reported in Egypt (90%), Gabon (97%), Central Africa Republic (100%), Democratic Republic of Congo (100%), Liberia (100%), Uganda (100%), and Rwanda (100%) [8-13]. In other countries of central Africa, the rates of HCV-4 are heterogeneous. For example in Cameroon, the HCV-4 prevalence is 31% [11].

Another important finding is that the 4h and 4e subtypes are the most common in our country. The most common subtype in Egypt is 4a, in Gabon 4c and in Cameroun 4f [11, 12]. Table 3 shows different subtypes in different countries [11-19]. These findings further support the idea that the origin, evolution, and dynamics of HCV-4 are difficult to determine, given the limited population-based epidemiological studies and phylogenetic analysis of this genotype in the geographic regions in which it is endemic, such as Burundi, Egypt and Central or West Africa. However, the results of this study corroborate the information available from small-scale field surveys from Central African countries and Cameroon that HCV-4 strains circulating in Central Africa and Cameroon are extremely heterogeneous and that the estimated date of the most recent common ancestors for HCV-4 was 1500 (95% CI: 1350-1700), suggesting that it probably has been endemic for a long time [13-16, 20-25].

According to the age of patients, our findings show an increasing prevalence with age. It seems possible that these results are due to mass vaccinations between 1940 and 1970 in Burundi and to ancestral practices such as scarification and circumcision. Some authors in Cameroon and Egypt reported the same factors. Indeed, an exponential spread of genotype 4 between 1920 and 1960 was detected in Cameroon, which coincided with the mass campaign against trypanosomiasis and mass vaccinations [13, 14, 23]. This great genetic diversity in sub-Saharan Africa might lead to the hypothesis that HCV-4 originated and propagated in Central and West Africa before spreading to other regions [13, 19-21].

It seems also important to emphasize that the LiPA method was unable to subtype a number of HCV-4 in our study. This finding was unexpected and suggests that the LiPA method, commonly used throughout the world, could be not adapted to African samples, particularly in countries where HCV-4 is predominant. Likewise, other authors have reported the same difficulty to subtype HCV-4, but in lower level than in our study [11]. The producers of reagents should be aware some more to guarantee a large diagnostic efficiency. At last, another interesting finding was that the genotype 3, not reported in the countries of eastern and central Africa, is however, found at 1.7% in our study.

Conclusion

The genotype 4 is the most frequent in Burundi. The subtype 4h seems to be predominant. Further, the genotype 3 rare in central Africa, is found in our country at 1.7%. The producers of reagents should be aware some more to assure a large diagnostic efficiency.

Competing interests

The authors declare no competing interests.

Authors’ contributions

All authors contributed somehow in different steps of the study. All authors read and agreed to the final version of this manuscript and contributed to its content and to the management of the patients.

Tables and figure

Table 1: characteristics of patients according to subtype 4; VL=viral load, SD=standard deviation
Table 2: genotypes and subtypes in Burundi
Table 3: distribution of HCV-4 subtypes in different countries
Figure 1: distribution of patients per age
References

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4):1333-1342. PubMed | Google Scholar

2. Madhava V, Burges C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis. 2002; 2(5):293-302. PubMed | Google Scholar

3. Ntagirabiri R, Baransaka E, Ndayiragije A, Niyongabo T. Prevalence of hepatitis C virus in Burundi: a nationwide survey. J Afr Hépatol Gastroentérol. 2014;8(1):25-28. PubMed | Google Scholar

4. Kuiken C, Simmonds P. Nomenclature and numbering of the hepatitis C virus. Methods Mol Biol. 2009;510:33-53. PubMed | Google Scholar

5. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):41-46. PubMed | Google Scholar

6. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski J P, Roudot-Thoraval F. The Observational VHC4 Study Group: Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat. 2007;14(7):460-467. PubMed | Google Scholar

7. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, Bouviers-Allais M, Trimoulet P, Chaix M L, Hézode C, Foucher J, Fontaine H, Roque-Afonso A-M, Gassin M, Schoerer E, Gaudy C, Roche B, Doffoël M, D’Alteroche L, Vallet S, Baazia Y, Pozetto B, Thibault V, Nousbaum J-B, Roulot D, Coppere H, Poinard T, Payan C, Izopet J. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J Med Virol. 2009; 81(12): 2029-2035. PubMed | Google Scholar

8. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antiviral Ther. 2005;10(1):1-11. PubMed | Google Scholar

9. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol. 2005;3(10 Suppl 2):S97-S101. PubMed | Google Scholar

10. Abdel-Aziz F, Habib M, Mohamed M K, Abdel-Hamid M, Gamil F, Madkour S, Mikhail N N, Thomas D, Fix A D, Strickland G T, Anwar W, Sallam I. Hepatitis C virus (HCV) infection in a community in the nile delta: Population description and HCV prevalence. Hepatology. 2000; 32 (1):111-115. PubMed | Google Scholar

11. Pasquier C, Njouom R, Ayoub A, Dubois M, Sartre M T, Vessière A, Timba I, Thonnon J, Izopet J, Nerrienet E. Distribution and heterogeneity of hepatitis C genotypes in hepatitis patients in Cameroon. J Med Virol. 2005;77(3):390-398. PubMed | Google Scholar

12. Njouom R , Caron M, Besson G, Ndong-Atome G R, Makuwa M, Pouillot R Nkoghe D, Leroy E, Kazanji M. Phylogeography, risk factors and genetic history of hepatitis C virus in Gabon, Central Africa. PLoS ONE. August 2012; 7(8):e42002. PubMed | Google Scholar

13. Kamal S M, Nasser I A. Hepatitis C Genotype 4: What we know and what we don’t yet know. Hepatology. 2008; 47(4):1371-1383. PubMed | Google Scholar

14. Ndjomou J, Pybus OG, Matz B. Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol. 2003;84(9):2333-2341. PubMed | Google Scholar

15. Tanaka Y, Agha S, Saudy N, Kurbanov F, Orito E, Kato T, Abo- Zeid M, Khalaf M, Miyakawa Y, Mizokami M. Exponential spread of hepatitis C virus genotype 4a in Egypt. J Mol Evol. 2004;58(2):191-195. PubMed | Google Scholar
16. Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, De Santis A, Nugi A, Amin G, Capocaccia L, Callea L, Rapicetta M, Badr G, Rocchi G. Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol. 1997;26(2):236-243. PubMed | Google Scholar

17. Rouabhi S, Sadelaud M, Chaabna-Mokrane K, Toumi W, Abenavoli L. Hepatitis C virus genotypes in north eastern Algeria: A retrospective study. World J Hepatol. 2013; 5(7): 393-399. PubMed | Google Scholar

18. Alashek W, Altagdi M. Risk factors and genotypes of hepatitis C virus infection in Libyan patients. Libyan J Med. 2008;3(4):162-165. PubMed | Google Scholar

19. Al Ashgar HL, Khan MQ, Al-Ahdal M, Al Thawadi S, Helmy AS, Al Qahtani A, Sanai FM. Hepatitis C genotype 4: genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia. Saudi J Gastroenterol. 2013;19(1):28-33. PubMed | Google Scholar

20. Simmonds P. Genetic diversity and evolution of hepatitis C virus—15 years on. J Gen Virol. 2004;85(11):3173-3188. PubMed | Google Scholar

21. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, Simmonds P. The origin of hepatitis C virus genotypes. J Gen Virol. 1997;78(2):321-328. PubMed | Google Scholar

22. Xu L-Z, Larzul D, Delaporte E, Bréchot C, Kremsdorf D. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol. 1994;75(9):2393-2398. PubMed | Google Scholar

23. Njouom R, Nerrienet E, Dubois M, Lachenal G, Rousselet D, Vessière A, Ayoub A, Pasquier C, Pouillot R. The hepatitis C virus epidemic in Cameroon: genetic evidence for rapid transmission between 1920 and 1960. Infect Genet Evol. 2007;7(3):361-367. PubMed | Google Scholar

24. Pybus O, Drummond A, Nakano T, Robertson BH, Rambaut A. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol. 2003;20(3):381-387. PubMed | Google Scholar

25. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis. 2000;182(3):698-707. PubMed | Google Scholar

---

**Table 1:** characteristics of patients according to subtype 4

| Subtype | Mean age ± SD | VL<800000UI/ml | VL>80000 UI/ml | Medium VL (UI/ml) |
|---------|---------------|----------------|----------------|------------------|
| 4       | 50.89 ± 11.78 | 37.0% (n=43)   | 63.0% (n=72)   | 2805 026         |
| 4e      | 53.22 ± 16.05 | 48.0% (n=12)   | 52.0% (n=13)   | 1341 843         |
| 4h      | 51.20 ± 12.46 | 73.0% (n=8)    | 27.0% (n=3)    | 988 818          |
| 4k      | 63.00 ± 14.14 | 50.0% (n=1)    | 50.0% (n=1)    | 541 760          |
| 4a/4c/4d| 52.86 ± 13.73 | 46.2% (n=6)    | 53.8% (n=7)    | 2605918          |
| Global  | 51.56 ± 13.12 | 42.2% (n=70)   | 57.8% (n=96)   | 1418248          |

VL=viral load, SD=standard deviation
### Table 2: Distribution of genotypes and subtypes in Burundi

| Genotype (n) | Subtype | Number of patients | Percentage |
|--------------|---------|--------------------|------------|
| Genotype 1 (n=10) | 1       | 9                  | 88.9%      |
|               | 1a      | 1                  | 11.1%      |
| Genotype 3 (n=3) | 3       | 2                  | 66.7%      |
|               | 3k      | 1                  | 33.3%      |
| Genotype 4 (n=166) | 4       | 115                | 69.3%      |
|               | 4h      | 25                 | 15.1%      |
|               | 4e      | 11                 | 6.6%       |
|               | 4k      | 2                  | 1.2%       |
|               | 4a/4c/4d | 13                | 7.8%       |

### Table 3: Distribution of HCV-4 subtypes in different countries

| Country               | HCV-4 (%) | HCV-4 Subtypes (%)                                      |
|-----------------------|-----------|--------------------------------------------------------|
| Egypt                 | 90        | 4a (55), 4 (24), 4o (7), 4m (3), 4l (3), 4n (2)        |
| Gabon                 | 97        | 4e (57.3), 4c (9.9), 4f (9.9), 4t(5,2), 4k(4,7), 4r (1,9), 4g (1,4) |
| Central African Republic | 100     | 4 (66.7), 4k (33.3)                                   |
| Democratic Republic of Congo | 100 | 4 (30), 4c (30), 4k (24), 4r (14), 4a (5)             |
| Cameroon              | 36        | 4f (22), 4 (5), 4t (5), 4k (5), 4e (1.4), 4o (1), 4p (1) |
| Liberia               | 100       | 4 (100)                                               |
| Uganda                | 100       | 4 (66.7), 4r (33.3)                                   |
| Tanzania              | 50        | 4 (100)                                               |
| Rwanda                | 100       | 4k (100)                                              |
| Sudan                 | 5         | 4, 4e, 4c/4d                                           |
| Tunisia               | 11        | 4k (5), 4a (3.6), 4 (2.6)                             |
| France                | 4–10      | 4d (2.3), 4a (2.2)                                    |
| Italy                 | 8.3       | 4d (5.9), 4 (2.4)                                     |
| Spain                 | 3–10      | 4c/4d (76.8), 4 (11.5), 4a (7.2), 4e (4.3)             |
| Greece                | 13.2      | 4a (78)                                               |
| Algerian              | 1.1       | 4a, 4a/4c/4d                                          |
| Libya                 | 32.6      | 4                                                     |
| Saudi Arabia          | 60-80     | 4a (48.4), 4d (39), 4n (6.25), 4m/4l/4r/4o (6.25)      |
Figure 1: Distribution of patients per age

Figure 1: distribution of patients per age